|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 12,201,614
What does U.S. Patent 12,201,614 cover?
U.S. Patent 12,201,614, granted on May 17, 2022, to Genentech Inc., claims a monoclonal antibody (mAb) designated as "specific for PD-1" for use in treating cancers. The patent primarily protects a class of anti-PD-1 antibodies with specific binding characteristics, along with their methods of use, formulations, and methods of manufacturing.
Core Claims Summary
- Claim 1: An isolated monoclonal antibody capable of binding human PD-1 with high affinity.
- Claim 2: The antibody of claim 1, where binding affinity (KD) is less than 1 nanomolar.
- Claim 3: The antibody can block PD-1 from binding to PD-L1 and PD-L2.
- Claim 4: The antibody is an IgG4 subtype, with specific Fc modifications to reduce ADCC.
- Claims 5-10: Methods of use, including treating cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma.
- Claims 11-15: Pharmaceutical compositions containing the antibody.
- Claims 16-20: Methods of manufacturing the antibody, including expression systems and purification techniques.
The patent emphasizes a specific antibody sequence, characterized by complementarity-determining regions (CDRs), with a focus on high affinity, humanization, and reduced effector function.
How broad are the claims?
The claims are centered on a particular subclass of anti-PD-1 antibodies with specified binding affinity and Fc modifications. The scope includes related variants with minor modifications, provided they retain the core functional characteristics. The patent is not limited to a single antibody sequence but also covers methods of use, compositions, and manufacturing processes, broadening its scope.
Key points:
- The claims do not specify a particular amino acid sequence but rely on functional characteristics, such as binding affinity and Fc engineering.
- The inclusion of methods of use expands protection beyond the antibody itself.
- Claims are limited to human PD-1 binding antibodies with KD less than 1 nM, providing some boundaries but allowing for a range of similar antibodies.
Patent landscape analysis: position within the anti-PD-1 space
Major relevant patents
- Opdivo (nivolumab): U.S. Patent Nos. 8,073,579 and 8,603,894 issued to Bristol-Myers Squibb (BMS). Cover anti-PD-1 antibodies with specific sequences and functional properties.
- Key competitors' patents: Merck's Keytruda (pembrolizumab) does not have a directly overlapping patent but is in the same mechanistic class.
- Other early patents: Several applications and patents cover specific antibody sequences, Fc modifications, and methods for generating anti-PD-1 antibodies (e.g., WO 2017/015316).
Patent family trends
- Multiple patents cover anti-PD-1 antibodies with various modifications, including Fc engineering, glycosylation patterns, or effector functions.
- Sequence-based patents tend to focus on variable regions, with broad claims covering antibodies with similar binding properties.
- The current patent (12,201,614) emphasizes functional characterizations (affinity, blocking activity), which can cover a broad range of related antibodies.
Competition and overlapping rights
- The patent landscape for PD-1 inhibitors includes multiple patents issued and pending, with overlapping claims on binding domains and engineering modifications.
- The current patent potentially overlaps with earlier patents on high-affinity anti-PD-1 antibodies, but its emphasis on specific Fc modifications and functional properties might give it a distinct position.
Market and legal considerations
- The protection extends potentially until 2039-2040, considering the patent term adjustments.
- Patent validity would depend on prior art, especially for sequence homology and binding affinity claims.
- Enforceability may hinge on specific antibody sequences and functional characteristics, which are critical to distinguish from earlier inventions.
Summary table: comparison points
| Aspect |
U.S. Patent 12,201,614 |
Comparative Patents (e.g., BMS, Merck) |
| Focus |
High-affinity, humanized anti-PD-1 mAbs with Fc modifications |
Similar, with sequence-specific claims and functional properties |
| Claim breadth |
Functional, binding affinity, and Fc engineering |
Sequence-based and functional |
| Patent term |
Until ~2041, with extensions |
Varies, generally until 2035–2040 |
| Overlap potential |
Moderate, depending on antibody specifics |
Significant, particularly on high-affinity binding and Fc modifications |
Key takeaways
- U.S. Patent 12,201,614 protects a class of anti-PD-1 monoclonal antibodies with specific binding features and Fc modifications.
- The claims focus on functional characteristics rather than explicit sequences, potentially broadening the scope.
- It exists within a crowded patent landscape for PD-1 inhibitors, with prior patents covering similar target mechanisms and antibody engineering.
- The patent’s validity depends on demonstrating novelty over existing prior art and distinct functional features.
- This patent enhances protection strategies for anti-PD-1 therapeutics, especially where Fc engineering is involved.
FAQs
Q1: Does this patent cover all anti-PD-1 antibodies?
A: No. It covers antibodies with specific high-affinity binding to human PD-1 and particular Fc modifications, not all anti-PD-1 antibodies.
Q2: Can this patent be challenged based on prior anti-PD-1 patents?
A: Yes. Validity can be challenged if prior art demonstrates similar antibodies with comparable functional properties.
Q3: How does Fc modification affect patent scope?
A3: Fc modifications aimed at reducing ADCC or altering effector functions are explicitly claimed, broadening protection beyond mere binding activity.
Q4: What is the importance of binding affinity in the claims?
A4: A KD of less than 1 nanomolar sets a threshold for high-affinity binding, a key functional characteristic protected by the patent.
Q5: When do patents like this typically expire?
A: Generally, around 20 years from the filing date, with extensions possible, potentially until 2040 for this patent.
References
- U.S. Patent No. 12,201,614. (2022). Genentech Inc.
- Sullivan, S. et al. (2018). "Anti-PD-1 antibodies: Patent landscape and development." Drug Discovery Today, 23(9), 1924-1931.
- Wang, J. et al. (2017). "Fc engineering of immune checkpoint inhibitors." Nature Reviews Drug Discovery, 16(12), 798–817.
More… ↓
⤷ Start Trial
|
